Assetmark Inc. Sells 13,534 Shares of IDEXX Laboratories, Inc. $IDXX

Assetmark Inc. reduced its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 20.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 51,251 shares of the company’s stock after selling 13,534 shares during the period. Assetmark Inc.’s holdings in IDEXX Laboratories were worth $32,744,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. STF Management LP increased its stake in IDEXX Laboratories by 1.3% in the 2nd quarter. STF Management LP now owns 1,240 shares of the company’s stock worth $665,000 after buying an additional 16 shares in the last quarter. Clearstead Trust LLC lifted its holdings in shares of IDEXX Laboratories by 1.1% in the 2nd quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock valued at $813,000 after acquiring an additional 16 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its position in shares of IDEXX Laboratories by 4.4% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company’s stock valued at $243,000 after purchasing an additional 16 shares during the last quarter. Moss Adams Wealth Advisors LLC raised its holdings in IDEXX Laboratories by 3.3% during the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company’s stock valued at $337,000 after buying an additional 17 shares during the period. Finally, Stratos Wealth Partners LTD. boosted its stake in shares of IDEXX Laboratories by 1.7% during the 2nd quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company’s stock worth $564,000 after purchasing an additional 18 shares during the period. 87.84% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, EVP George Fennell sold 11,345 shares of IDEXX Laboratories stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total value of $7,337,038.40. Following the completion of the transaction, the executive vice president owned 9,823 shares in the company, valued at approximately $6,352,730.56. This trade represents a 53.60% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.98% of the stock is owned by insiders.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $629.35 on Friday. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98. The stock has a market cap of $50.25 billion, a PE ratio of 48.15, a P/E/G ratio of 3.75 and a beta of 1.67. The stock has a 50 day moving average price of $684.99 and a 200 day moving average price of $667.02. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the prior year, the firm earned $2.53 EPS. IDEXX Laboratories’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on IDXX shares. Leerink Partners set a $785.00 target price on shares of IDEXX Laboratories in a research note on Monday, November 3rd. Piper Sandler decreased their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research report on Monday. Weiss Ratings lowered IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. Barclays cut their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Finally, Morgan Stanley increased their price objective on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Seven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $783.33.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.